Kolexia
Moullet Isabelle Hématologie
Moullet Isabelle
Hématologie
Hôpital Lyon Sud
Pierre-Bénite, France
52 Activités
14 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Métastase tumorale Tumeurs des glandes endocrines Tumeurs de l'ovaire Effets secondaires indésirables des médicaments Douleur chronique Tumeurs du sein triple-négatives Carcinome épithélial de l'ovaire Fistule vésicale

Collaborateurs

Voir plus
Tredan Olivier
Tredan Olivier
Centre Léon-Bérard, Lyon, France
Orfeuvre Hubert
Orfeuvre Hubert
Hôpital Fleyriat, Bourg-en-Bresse, France
Ardisson Philippe
Ardisson Philippe
Clinique de la Sauvegarde, Lyon, France
Bachelot Thomas
Bachelot Thomas
Centre Léon-Bérard, Lyon, France

Industries

Voir plus
A+A
162 collaboration(s)
Dernière en 2023
B3TSI
66 collaboration(s)
Dernière en 2023
EXAFIELD
20 collaboration(s)
Dernière en 2023
Inter-View Partners France
18 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer: Phase III Randomized Multicenter Trial Comparing Continued Maintenance Therapy With the Bevacizumab + Taxane Versus Bevacizumab + Substituting Exemestane in Patients With Metastatic Breast Cancer or Locally Advanced With Estrogen Receptor Positive and Having at Least a Stable Disease After 16 to 18 Weeks of Treatment With Bevacizumab + Taxane.
Essai Clinique (ARCAGY/ GINECO GROUP)   05 septembre 2023
DONEPEZOX: Evaluation of the Efficacy of Donepezil in the Treatment of Oxaliplatin-induced Peripheral Neuropathy: Proof of Concept Study
Essai Clinique (CHU Clermont-Ferrand)   25 avril 2023
First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study.
Breast (Edinburgh, Scotland)   30 septembre 2020
Analysis of the StoRM cohort reveals physical activity to be associated with survival in metastatic breast cancer.
Scientific reports   01 juillet 2020
Cancers bronchiques non à petites cellules avec mutation HER2 : étude du microenvironnement immunitaire et efficacité des anti-PD-1
24e Congrès CPLF   01 janvier 2020
SToRM: A clinical cohort to identify genetic variability related to metastatic phenotypes
Abstract Book of the 42nd ESMO Congress (ESMO 2017) 8-12 September 2017, Madrid, Spain   01 septembre 2017
A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group study.
Annals of oncology : official journal of the European Society for Medical Oncology   24 février 2016
Abstract P1-08-06: SToRM: A prospective clinical trial of 1502 metastatic breast cancer (mBC) patients with detail of clinical presentation, molecular subtype, treatment modalities, prognosis and GWAS genotyping
Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium   15 février 2016
Arobase: A phase III trial of exemestane (Exe) and bevacizumab (BEV) as maintenance therapy in patients (pts) with metastatic breast cancer (MBC) treated in first line with paclitaxel (P) and BEV—A Gineco study.
2014 ASCO Annual Meeting I   20 mai 2014
Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study.
Bulletin du cancer   04 novembre 2011